Thirdly, the recent administration of third-generation osimertinib monotherapy as well as the combination of osimertinib and bavaciumab also challenges the role of afatinib on the treatment of advanced EGFR-mutant NSCLC [36,37]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.